"Cytochrome P-450 CYP2B6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme subtype that oxidizes a diverse array of XENOBIOTICS. The expression of CYP2B6 varies widely between individuals which is due to the high rate of GENETIC POLYMORPHISMS. Examples of drugs metabolized by CYP2B6 include BUPROPION; efavirenz; CYCLOPHOSPHAMIDE; and MEPERIDINE.
| Descriptor ID |
D065702
|
| MeSH Number(s) |
D08.244.453.005.575 D08.244.453.491.344 D08.811.682.690.708.170.010.575 D08.811.682.690.708.170.450.344 D12.776.422.220.453.010.575 D12.776.422.220.453.491.344
|
| Concept/Terms |
Cytochrome P-450 CYP2B6- Cytochrome P-450 CYP2B6
- CYP2B6, Cytochrome P-450
- Cytochrome P 450 CYP2B6
- P-450 CYP2B6, Cytochrome
- CYPIIB6
- 1,4-Cineole 2-exo-Monooxygenase
- 1,4 Cineole 2 exo Monooxygenase
- 2-exo-Monooxygenase, 1,4-Cineole
- Cytochrome P450 2B6
- P450 2B6, Cytochrome
- CYP2B6
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2B6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2B6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2B6" by people in this website by year, and whether "Cytochrome P-450 CYP2B6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2B6" by people in Profiles.
-
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2024 03; 115(3):576-594.
-
Genetic variants in CYP2B6 and HSD17B12 associated with risk of squamous cell carcinoma of the head and neck. Int J Cancer. 2022 08 15; 151(4):553-564.
-
The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment. New Dir Child Adolesc Dev. 2020 May; 2020(171):107-133.
-
Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. Nicotine Tob Res. 2020 May 26; 22(6):910-918.
-
Common and Rare Variants Genetic Association Analysis of Cigarettes per Day Among Ever-Smokers in Chronic Obstructive Pulmonary Disease Cases and Controls. Nicotine Tob Res. 2019 05 21; 21(6):714-722.
-
Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis. Endocrinology. 2018 06 01; 159(6):2435-2446.
-
CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil. An Acad Bras Cienc. 2017 May; 89(1 Suppl?0):497-504.
-
CYP2B6-G516T genotype influences plasma efavirenz concentration in a Hong Kong population, allowing potential individualization of therapy. HIV Med. 2014 Jan; 15(1):63-4.
-
Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis. Int J Mol Sci. 2013 Apr 16; 14(4):8381-92.
-
Genetic determinants of the ankle-brachial index: a meta-analysis of a cardiovascular candidate gene 50K SNP panel in the candidate gene association resource (CARe) consortium. Atherosclerosis. 2012 May; 222(1):138-47.